Is Dual Therapy With Raltegravir and Protease Inhibitors a Feasible Option in Rescue Strategy in Hiv-1 Infection?

Jeffrey A. Anderson, Hongyu Jiang, Xiao Ding, Leslie Petch, Terri Journigan, Susan A. Fiscus, Richard Haubrich, David Katzenstein, Ronald Swanstrom, Roy M. Gulick, , Genotypic Susceptibility Scores and HIV Type 1 RNA Responses in Treatment-Experienced Subjects with HIV Type 1 Infection AIDS Research and Human Retroviruses. ,vol. 24, pp. 685- 694 ,(2008) , 10.1089/AID.2007.0127

Pablo Tebas, Jiameng Zhang, Kevin Yarasheski, Scott Evans, Margaret A Fischl, Abby Shevitz, Judith Feinberg, Ann C Collier, Cecilia Shikuma, Barbara Brizz, Fred Sattler, AIDS Clinical Trials Group, Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). Journal of Acquired Immune Deficiency Syndromes. ,vol. 45, pp. 193- 200 ,(2007) , 10.1097/QAI.0B013E318042E204

Sandra de Meyer, Tony Vangeneugden, Ben van Baelen, Els de Paepe, Herwig van Marck, Gaston Picchio, Eric Lefebvre, Marie-Pierre de Béthune, Resistance Profile of Darunavir : Combined 24-Week Results from the POWER Trials AIDS Research and Human Retroviruses. ,vol. 24, pp. 379- 388 ,(2008) , 10.1089/AID.2007.0173

Roy M Gulick, Heather J Ribaudo, Cecilia M Shikuma, Christina Lalama, Bruce R Schackman, William A Meyer, Edward P Acosta, Jeffrey Schouten, Kathleen E Squires, Christopher D Pilcher, Robert L Murphy, Susan L Koletar, Margrit Carlson, Richard C Reichman, Barbara Bastow, Karin L Klingman, Daniel R Kuritzkes, AIDS Clinical Trials Group, A5095 Study Team, Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA. ,vol. 296, pp. 769- 781 ,(2006) , 10.1001/JAMA.296.7.769

Beatriz Grinsztejn, Bach-Yen Nguyen, Christine Katlama, Jose M Gatell, Adriano Lazzarin, Daniel Vittecoq, Charles J Gonzalez, Joshua Chen, Charlotte M Harvey, Robin D Isaacs, Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial The Lancet. ,vol. 369, pp. 1261- 1269 ,(2007) , 10.1016/S0140-6736(07)60597-2

Mark Nelson, Keikawus Arast??h, Bonaventura Clotet, David A Cooper, Keith Henry, Christine Katlama, Jacob P Lalezari, Adriano Lazzarin, Julio S. G Montaner, Mary O??Hearn, Peter J Piliero, Jacques Reynes, Benoit Trottier, Sharon L Walmsley, Calvin Cohen, Joseph J Eron, Daniel R Kuritzkes, Joep Lange, Hans-J??rgen Stellbrink, Jean-Fran??ois Delfraissy, Neil E Buss, Lucille Donatacci, Cynthia Wat, Lynn Smiley, Martin Wilkinson, Adeline Valentine, Denise Guimaraes, Ralph DeMasi, Jain Chung, Miklos P Salgo, Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials Journal of Acquired Immune Deficiency Syndromes. ,vol. 40, pp. 404- 412 ,(2005) , 10.1097/01.QAI.0000185314.56556.C3

Schlomo Staszewski, Javier Morales-Ramirez, Karen T. Tashima, Anita Rachlis, Daniel Skiest, James Stanford, Richard Stryker, Philip Johnson, Dominic F. Labriola, Dianne Farina, Douglas J. Manion, Nancy M. Ruiz, Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults The New England Journal of Medicine. ,vol. 341, pp. 1865- 1873 ,(1999) , 10.1056/NEJM199912163412501